In 2003, there seemed to be good reasons to leave weight-loss drugs out of the benefit, write Inmaculada Hernandez of the University of California, San Diego, and coauthors in their September 2023 editorial in the Journal of General Internal Medicine, Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform. When members of Congress worked on the Part D benefit, the drugs available on the market were known to have limited effectiveness and unpleasant side effects
10.1038/nature22378 95 SongS.GuoR.MehmoodA.ZhangL.YinB.YuanC.et al (2022)
However, in compounded form, patients may need to draw the solution into the needle themselves before injecting it
Reach us via chat, email, or phone 7 days a week
There have been Weight loss medications may alter the efficacy of oral birth control, and weight loss may increase fertility in some cases
Compounded versions of semaglutide and tirzepatidesuch as those available through telehealth platformshave not undergone the same FDA approval process